Friends Or Foes? The Changing Regulator/Industry Relationship In Europe
This article was originally published in SRA
Recent years have seen the pharmaceutical industry working more closely with European regulators as the nature of drug development changes, with companies increasingly being urged to engage at an ever earlier stage with regulatory agencies and health technology assessment bodies to discuss their development programs.
You may also be interested in...
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.